Financials

  • Market Capitalization 1.5922 M
  • Employee 17
  • Founded 1988
  • CEO David A. Dodd
  • Website www.geovax.com
  • Headquarter Delaware, United States
  • FIGI BBG000BGGJD8
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-0.51
Relación precio/flujo de caja
3.24

GeoVax Labs Inc

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated.

Noticias